Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20706169 | 0.88 | CES2 (0.34) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22297128 | 0.86 | CYP2C19 (0.37) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20353236 | 0.83 | MEN1 (0.38) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL22340971 | 0.81 | CES2 (0.45) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13553383 | 0.81 | CES2 (0.45) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23173307 | 0.81 | MEN1 (0.35) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL24309097 | 0.81 | CYP2C19 (0.41) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12139725 | 0.81 | CYP2C19 (0.41) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12237951 | 0.81 | CYP2C19 (0.41) | MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20322404 | 0.81 | CES2 (0.45) | MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239852-A1 | AMYLIN RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2024-07-18 | — | — | US | disclosed |
| US-20200407409-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | CHEN JIANHE (CN) | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239852-A1 | AMYLIN RECEPTOR AGONISTS | GLP1R, GPR119, GIPR | MEN1 828/4885KMT2A 4387/4885SMN1; SMN2 1601/4885 |
| US-20200407409-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | EGFR, LDLR, FFAR2 | MEN1 3956/4885KMT2A 3113/4885SMN1; SMN2 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.